Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Affiliations

• ¹ The Alfred Hospital and Monash University, Melbourne, VIC, Australia. [email protected].
• ² National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.
• ³ Hospital Universitario y Politécnico La Fe, Valencia, Spain.
• ⁴ CIBERONC, Instituto Carlos III, Madrid, Spain.
• ⁵ Centre Hospitalier-Le Mans, Le Mans, France.
• ⁶ Almazov National Medical Research Center, Saint Petersburg, Russia.
• ⁷ Seoul National University Hospital, Seoul, South Korea.
• ⁸ University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
• ⁹ Norton Cancer Institute, Louisville, KY, USA.
• ¹⁰ Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
• ¹¹ Evaggelismos General Hospital, Athens, Greece.
• ¹² CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, QC, Canada.
• ¹³ Eastern Health and Monash University, Melbourne, VIC, Australia.
• ¹⁴ University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA, USA.
• ¹⁵ George Papanicolaou General Hospital, Thessalonica, Greece.
• ¹⁶ Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa.
• ¹⁷ Heartlands Hospital, Birmingham, UK.
• ¹⁸ University of Fukui Hospital, Fukui, Japan.
• ¹⁹ Chinese Academy of Medical Sciences, Tianjin, China.
• ²⁰ AbbVie Inc, North Chicago, IL, USA.
• ²¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.